• Publications
  • Influence
A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection
TLDR
Directing the immune response to a non-immunodominant but functionally relevant serotype-specific dengue epitope of the four DENV serotypes, displayed on a VLP platform, can help minimize the risk of inducing disease-enhancing antibodies while eliciting effective tetravalent seroconversion.
Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo
TLDR
The creation and characterization of a novel non-replicating recombinant particulate vaccine candidate, produced by co-expressing the E proteins ofDENV-1 and DENV-2 in P. pastoris, and the results obtained with these bivalent mVLPs suggest the feasibility of incorporating the E protein of DENv-3 and DENVs-4 to create a tetravalent mVLP vaccine.
Cocculus hirsutus-derived phytopharmaceutical drug has potent anti-dengue activity
TLDR
Evidence is provided of the pan anti-dengue potential of C. hirsutus-based phytopharmaceutical drug as determined through in vitro and in vivo experiments and a program to develop a safe and effective C. HirsUTus-derived phytophile drug for the treatment of dengue has been initiated.
Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
TLDR
Data reveal that P. pastoris-producedDENV-3 E VLPs not only preserve the antigenic integrity of the major neutralizing epitopes, but also elicit potent DENV-2 virus-neutralizing antibodies, which could pave the way for a DENV E-based, inexpensive, safe, and efficacious tetravalent sub-unit vaccine, for use in resource-poor dengue endemic countries.
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies
TLDR
This work demonstrates the inherent potential of P. pastoris-expressed DENV-1 E glycoprotein to self-assemble into VLPs eliciting predominantly homotypic neutralizing antibodies, and justifies an investigation of the last remaining serotype, namely,DENV-4, to assess if it also shares the desirable vaccine potential manifested by the remaining three DENV serotypes.
Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.
TLDR
VLP-based nonreplicative vaccine approach is explored and developed, paving the way for the evaluation of a DENV E-based tetravalent dengue vaccine candidate, as an alternative to live virus-based d Dengue vaccines.
Dengue-specific subviral nanoparticles: design, creation and characterization
TLDR
A strategy to co-express and co-purify Hepatitis B virus surface (S) antigen in two forms: independently and as a fusion with EDIII, which may be potentially useful in diagnostic, therapeutic and prophylactic applications.
Dengue and Zika Virus Infections Are Enhanced by Live Attenuated Dengue Vaccine but Not by Recombinant DSV4 Vaccine Candidate in Mouse Models
TLDR
A head-to-head comparison of the putative ADE-competence of murine polyclonal antibodies induced by DSV4, Dengvaxia and an ‘in house’ tetravalent mixture of all four laboratory DENV strains, TV DENV, using established mouse models of DENV and ZIKV ADE finds whole virus-based dengue vaccines may be associated with ADE risk, despite their potent virus-neutralising capacity.
Next generation designer virus-like particle vaccines for dengue
TLDR
This article focuses on two new yeast-produced tetravalent dengue envelope domain III-displaying virus-like particulate vaccine candidates reported in early 2018 and reviews the rationale underlying their design, and pre-clinical data which suggest that these may offer promising alternate options.
...
...